Lipid Profile in Early and Late Stage among Patients with Nephrotic Syndrome-Related Chronic Kidney Disease in Dr. Hasan Sadikin General Hospital Bandung, Indonesia in 2016−2019

Haya Hanif Mahardika, Ahmedz Widiasta, Viramitha Kusnandi Rusmil

Abstract


Background: Chronic kidney disease (CKD) is a major health problem in children with an increased prevalence globally. CKD is strongly associated with Nephrotic Syndrome (NS) and dyslipidemia, which become a progressive factor of CKD. This study aimed to describe the lipid profile of children with CKD and NS in Dr. Hasan Sadikin General Hospital Bandung, Indonesia.

Methods: An observational-retrospective study was conducted with a cross-sectional design involving 150 medical records of children aged 1−18 years who were diagnosed with CKD with NS. Lipid profile data, including total cholesterol, triglycerides, LDL, and HDL, were collected from 2016−2019 using the total sampling method. Subjects with incomplete lipid profile data were excluded from the study.

Results: Among the fifty-two children that were eligible and fulfilled the inclusion criteria, 88.5% were diagnosed with stage 1 CKD, and 32.7% were aged between 6−11 years and boys were predominant (67.3%). Lipid profile changes were found in the LDL, HDL, and total cholesterol serum levels between CKD stage I and II–V.

Conclusions: Lipid profile of CKD pediatric patients with NS in Dr. Hasan Sadikin General Hospital Bandung in 2016−2019 showed hypertriglyceridemia and hypercholesterolemia. Most subjects were in stage I of CKD and Steroid-Resistant Nephrotic Syndrome, and comparison between stages of CKD and types of nephrotic syndrome is lacking. A prospective analytical study would be more reliable in proofing its significance.


Keywords


Chronic kidney disease, cholesterol, lipid profile, nephrotic syndrome, triglyceride

Full Text:

PDF

References


  1. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713–35.
  2. Levin A, Stevens PE., Bilous RW, Coresh J, De Fransisco ALM, De Jong PE, et al. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.
  3. Becherucci F, Roperto RM, Materassi M, Romagnani P. Chronic kidney disease in children. Clin Kidney J. 2016;9(4):583-91.
  4. Halle MP, Lapsap CT, Barla E, Fouda H, Djantio H, Moudze BK, Akazong CA, Priso EB. Epidemiology and outcomes of children with renal failure in the pediatric ward of a tertiary hospital in Cameroon. BMC Pediatr. 2017;17(1):202.
  5. Badan Penelitian dan Pengembangan Kesehatan. RISKESDAS 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan;2018.
  6. Widiasta A, Pardede SO, Rachmadi D. Correlation between LDL, HDL, total cholesterol , and triglyceride with the degree of chronic kidney disease in children. Am J Clin Med Res. 2017;5(1): 1–5.
  7. Hussain N, Zello JA, Vasilevska-Ristovska J, Banh TM, Patel VP, Patel P, et al. The rationale and design of Insight into Nephrotic Syndrome: Investigating Genes, Health and Therapeutics (INSIGHT): a prospective cohort study of childhood nephrotic syndrome. BMC Nephrol. 2013;14:25.
  8. Pandey JC, Prasad CK. Lipid profile abnormalities in nephrotic syndrome. Asian J Biomed Pharm Sci. 2016;6(54): 17–19.
  9. Dnyanesh D, Dnyanesh S, Shenoy V. A study of serum lipids in nephrotic syndrome in children. IOSR J Dent Med Sci 2014;13(3): 1–6.
  10. Krishnaswamy D, Indumati V, Satishkumar D, Vijay V, Shekanawar Maharudra, Maligi Amareshwara, et al. Serum proteins, initial and follow-up lipid profile in children with nephrotic syndrome. Int J Appl Biol Pharm Technol. 2011;2(3): 59–64.
  11. Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease. J Nephropathol. 2014;3(3):99–104.
  12. Wilson AC, Schneider MF, Cox C, Greenbaum LA, Saland J, White CT, et al. Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(12):2759–65.
  13. National Institute of Child Health and Human Development US Department of Health and Human Services. The NICHD study of early child care and youth development: - findings for children up to age 4 1/2 years [Internet]. Washington, DC: US Government Printing Office; 2006. [Cited 2021 August 28]. Available from: https://www.nichd.nih.gov/publications/product/20
  14. Stewart J, McCallin T, Martinez J, Chacko S, Yusuf S. Hyperlipidemia. Pediatr Rev. 2020;41(8):393–402.
  15. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128 Suppl 5(Suppl 5):S213–56.
  16. Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41–52.
  17. Chan DT, Dogra GK, Irish AB, Ooi EM, Barrett PH, Chan DC, et al. Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. J Lipid Res. 2009;50(12):2524–31.
  18. Blaton V. Dyslipidemia at chronic renal failure. EJIFCC. 2009;20(1):59–66.
  19. Ooi EM, Chan DT, Watts GF, Chan DC, Ng TW, Dogra GK, et al. Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease. J Lipid Res. 2011;52(4):794–800.
  20. Saland JM, Pierce CB, Mitsnefes MM, Flynn JT, Goebel J, Kupferman JC, et al. Dyslipidemia in children with chronic kidney disease. Kidney Int. 2010;78(11):1154–63.
  21. Vaziri ND. HDL abnormalities in nephrotic syndrome and chronic kidney disease. Nat Rev Nephrol. 2016;12(1):37–47.
  22. Mitsnefes MM. Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol. 2012;23(4):578–85.
  23. Tian J, Niu L, An X. Cardiovascular risks in chronic kidney disease pediatric patients. Exp Ther Med. 2017;14(5):4615–9.




DOI: https://doi.org/10.15850/amj.v10n1.2524

Article Metrics

Abstract view : 274 times
PDF - 244 times


 This Journal indexed by

                  

          

 

Creative Commons License
AMJ is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

 


View My Stats